Ascentage Pharma Group International
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AAPGV research report →
Companywww.ascentage.cn
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma.
- CEO
- Dajun Yang
- IPO
- 2025
- Employees
- 574
- HQ
- Suzhou, CN
Price Chart
Valuation
- Market Cap
- $127.31M
- P/E
- -10.12
- P/S
- 22.02
- P/B
- 9.40
- EV/EBITDA
- -10.79
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 84.09%
- Op Margin
- -210.42%
- Net Margin
- -216.74%
- ROE
- -123.61%
- ROIC
- -33.71%
Growth & Income
- Revenue
- $980.65M · 341.77%
- Net Income
- $-405,433,000 · 56.20%
- EPS
- $-0.75 · 94.31%
- Op Income
- $-369,730,000
- FCF YoY
- 82.67%
Performance & Tape
- 52W High
- $18.00
- 52W Low
- $16.50
- 50D MA
- $17.41
- 200D MA
- $17.41
- Beta
- 1.10
- Avg Volume
- 497.68K
Get TickerSpark's AI analysis on AAPGV
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our AAPGV Coverage
We haven't published any research on AAPGV yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AAPGV Report →